Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mariusz L. Hartman"'
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7891 (2023)
Despite significant advances in targeted therapies against the hyperactivated BRAFV600/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cel
Externí odkaz:
https://doaj.org/article/b42a5f3619d54b16aef21cc4dc543c0e
Autor:
Mariusz L. Hartman, Magdalena Rogut, Aleksandra Mielczarek-Lewandowska, Michal Wozniak, Malgorzata Czyz
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 11, p 3749 (2020)
Melanoma remains incurable skin cancer, and targeting heat shock protein 90 (HSP90) is a promising therapeutic approach. In this study, we investigate the effect of 17-aminogeldanamycin, a potent HSP90 inhibitor, on nuclear factor-kappa B (NF-κB) ac
Externí odkaz:
https://doaj.org/article/b17844a103d9475eb31cc3bfbd1a3573
Autor:
Mariusz L. Hartman
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 8, p 2980 (2020)
Resisting cell death is a hallmark of cancer. Disturbances in the execution of cell death programs promote carcinogenesis and survival of cancer cells under unfavorable conditions, including exposition to anti-cancer therapies. Specific modalities of
Externí odkaz:
https://doaj.org/article/8ca342a816364fefa99234feea7c2fc4
Publikováno v:
Cells, Vol 9, Iss 1, p 142 (2020)
The clinical benefit of MAPK pathway inhibition in BRAF-mutant melanoma patients is limited by the development of acquired resistance. Using drug-naïve cell lines derived from tumor specimens, we established a preclinical model of melanoma resistanc
Externí odkaz:
https://doaj.org/article/b7f9264462294f6ab57429d4ed02e5a1
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 17, p 4203 (2019)
Cancer cell phenotype largely depends on oxygen availability. The atmospheric oxygen concentration (21%) used in in vitro studies is much higher than in any human tissue. Using well-characterized patient-derived melanoma cell lines, we compared: (i)
Externí odkaz:
https://doaj.org/article/2db8d0258d424ac1ae52b6834ffcd095
Autor:
Mariusz L. Hartman, Malgorzata Czyz
Publikováno v:
Cell Death & Differentiation.
Proteins from the BCL-2 family control cell survival and apoptosis in health and disease, and regulate apoptosis-unrelated cellular processes. BCL-Gonad (BCL-G, also known as BCL2-like 14) is a non-typical protein of the family as its long isoform (B
Autor:
Aleksandra Mielczarek-Lewandowska, Mariusz L. Hartman, Julita A. Talaj, Anna Gajos-Michniewicz, Malgorzata Czyz
Publikováno v:
Cancer Letters. 499:122-136
BRAFV600- and MEK1/2-targeting therapies rarely produce durable response in melanoma patients. We investigated five BRAFV600E melanoma cell lines derived from drug-naive tumor specimens to assess cell death response to encorafenib (Braftovi), a recen
Autor:
Mariusz L. Hartman, Malgorzata Czyz
Publikováno v:
Archives of Dermatological Research. 312:385-392
TYRP1 mRNA is of interest due to its potential non-coding role as a sponge sequestering tumor-suppressive miRs in melanoma. To our knowledge, there is no report on changes inTYRP1expression in melanomas after development of resistance to targeted the
Autor:
Mariusz L. Hartman, Anna Gajos-Michniewicz, Malgorzata Czyz, Marta Osrodek, Malgorzata Sztiller-Sikorska
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2019 (2019)
Journal of Oncology, Vol 2019 (2019)
Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation prog
Publikováno v:
Molecular Carcinogenesis. 58:588-602
We have extensively studied the phenotypic heterogeneity of patient-derived melanoma cells. Here, whole-exome sequencing revealed novel variants of genes associated with the MAPK, NOTCH, Hippo, cell-cycle, senescence, and ubiquitin-dependent pathways